Successful treatment with docetaxel and prednisolone for paxlitaxel and carboplatin-resistant prostate cancer
A 60-year-old man was examined at a local clinic for difficulty in urinating, and was diagnosed with prostatic hypertrophy. He was referred to our department because his prostate-specific antigen (PSA) level was elevated (276 ng/ml). His Gleason score was 4＋3, there was one bone metastasis in the le...
| Veröffentlicht in: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 59(2013), 5 vom: 26. Mai, Seite 301-4 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , , |
| Format: | Aufsatz |
| Sprache: | Japanese |
| Veröffentlicht: |
2013
|
| Zugriff auf das übergeordnete Werk: | Hinyokika kiyo. Acta urologica Japonica |
| Schlagworte: | Case Reports Journal Article Antineoplastic Agents Antineoplastic Agents, Hormonal Antineoplastic Agents, Phytogenic Taxoids Docetaxel 15H5577CQD Prednisolone 9PHQ9Y1OLM mehr... |
| Zusammenfassung: | A 60-year-old man was examined at a local clinic for difficulty in urinating, and was diagnosed with prostatic hypertrophy. He was referred to our department because his prostate-specific antigen (PSA) level was elevated (276 ng/ml). His Gleason score was 4＋3, there was one bone metastasis in the left ileac bone, and multiple lung metastases were present. The patient was accordingly diagnosed with stage D2 prostate cancer. Lutenizing hormone-releasing hormone (LH-RH) analogue treatment was initiated in April 1999, and 9 months later the PSA level had decreased to 4.3 ng/ml. Six years and 9 months after the start of hormone therapy, the cancer had developed into castration-resistant prostate cancer and the PSA level had risen to 43.8 ng/ml. Paclitaxel-carboplatin therapy was therefore initiated. Eight months after the start of chemotherapy, the PSA level had decreased to 25.9 ng/ml, but 6 years and 1 month later it had risen to 925 ng/ml, and the chemotherapy was discontinued. Docetaxel-predonine therapy was initiated in March 2012. Three months after the start of chemotherapy, the PSA level had decreased to 3.1 ng/ml, and the bone metastasis was reduced |
|---|---|
| Beschreibung: | Date Completed 25.09.2013 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
| ISSN: | 0018-1994 |